Optimizing surgical outcome of auricular keloid with a novel multimodal approach

Sci Rep. 2022 Mar 3;12(1):3533. doi: 10.1038/s41598-022-07255-8.

Abstract

Various treatments are available for auricular keloids, but none has an absolute advantage. A practical and safe therapy to optimize the surgical outcome for auricular keloids is needed. We adopted a multimodal treatment of surgical enucleation, core fillet flap reconstruction, intraoperative corticosteroid injection, and immediate postoperative radiotherapy. There were no routine intralesional corticosteroid injections during follow-up. Keloid recurrences, complications, and risk factors for recurrences were analyzed. The outcome was compared with other published literatures. 45 auricular keloids were included in this study. 85.7% were female with an average age of 27.1 ± 7.5 years, and averaged size was 1.8 × 1.2 ± 0.9 × 0.6 cm. 71.1% were located at ear helix with 28.9% at the ear lobe. Nine keloids were classified as Chang-Park classification type I, 30 for type II, two for type III, and four for IV. The average radiation dosage was 1578.6 cGy. The recurrence rate was 6.7% at an average 24.1-month follow-up. There were no complications of surgery, radiotherapy, and intralesional corticosteroid injection. Our recurrence rate was lower than those in mono-adjuvant therapies of intraoperative corticosteroid injection or radiotherapy. This one-session multimodal approach optimizes treating auricular keloids with a low recurrence rate and minimal post-radiation and long-term corticosteroid injection-related complications.

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Ear Auricle* / surgery
  • Female
  • Humans
  • Injections, Intralesional
  • Keloid* / pathology
  • Keloid* / surgery
  • Recurrence
  • Treatment Outcome
  • Young Adult

Substances

  • Adrenal Cortex Hormones